Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.49 |
| ▸ | HTR2C | P28335 | 9/20 | 0.42 |
| ▸ | HTR2B | P41595 | 7/20 | 0.41 |
| ▸ | HTR2A | P28223 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21818995 | 0.85 | HTR7 (0.48) | HTR7HTR2CHTR2BHTR2AMGLL | |
| SCHEMBL21818664 | 0.84 | HTR2C (0.56) | HTR7HTR2CHTR2BHTR2A | |
| SCHEMBL21894372 | 0.82 | CD274 (0.45) | HTR7HTR2CHTR2BHTR2AALDH1A1 | |
| SCHEMBL21893446 | 0.81 | ASIC3 (0.49) | HTR2CHTR2BHTR2AMAPT | |
| SCHEMBL21893457 | 0.80 | HTR2A (0.41) | HTR2CHTR2BHTR2A | |
| SCHEMBL21893923 | 0.79 | HTR2C (0.40) | HTR2CHTR2BHTR2AMGLL | |
| SCHEMBL21893925 | 0.79 | PDE4B (0.39) | HTR2CHTR2BHTR2A | |
| SCHEMBL21894375 | 0.79 | HTR2C (0.47) | HTR2CHTR2BHTR2A | |
| SCHEMBL16089624 | 0.78 | P2RX7 (0.47) | HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL16037648 | 0.77 | P2RX7 (0.46) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | HTR7 704/4885HTR2C 516/4885HTR2B 301/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | HTR7 326/4885HTR2C 128/4885HTR2B 224/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | HTR7 704/4885HTR2C 516/4885HTR2B 301/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | HTR7 704/4885HTR2C 516/4885HTR2B 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.